Traws Pharma GAAP EPS of -$0.11, revenue of $2.73M
Source: SeekingAlpha
2025-08-14 07:05:21 ET
More on Traws Pharma
- Traws Pharma advances antiviral pipeline with multiple regulatory submissions
- Financial information for Traws Pharma
Read the full article on Seeking Alpha
For further details see:
Traws Pharma GAAP EPS of -$0.11, revenue of $2.73M
Traws Pharma Inc.
NASDAQ: TRAW
TRAW Trading
11.57% G/L:
$1.7405 Last:
1,153,558 Volume:
$1.55 Open:
TRAW Latest News
May 15, 2026 07:00:00 am
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial ResultsMay 08, 2026 07:30:00 am
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus InfectionsApril 15, 2026 04:01:00 pm
Traws Pharma Reports Full Year 2025 Results and Provides Business HighlightsTRAW Stock Data
$15,422,373
6,872,146
2.64%
11
N/A
Biotechnology & Life Sciences
Healthcare
US
Newtown
